

86
81

Señores

DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Santafé de Bogotá, D.C.

en caja
anexa.

Re.: Expediente No. 00 - 52.321

Solicitud de Patente

Debidamente traducidas, adjunto acompaño las copias oficiales de las solicitudes de patente básicas estadounidenses No. 09/352.616, No. 09/439.313, No. 09/443.686, No. 09/483.672, No. 09/536.857, No. 09/586.100 (2), No. 09/570.737, No. 09/593.793 (2) y No. 09/605.783, y la solicitud de patente básica inglesa No. 0015747.9 de Junio 27 del 2000, las cuales le solicito agregar a este expediente para los efectos legales respectivos.

De Ustedes atentamente,

GERMAN CASTILLO GRAU

T.P. No. 2978 del C.S.J.



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

82

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Gersey

Dated 2 August 2000





83
88

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

28 JUN 00 E548473-1 D02029
P01/7700 0.00-0015747.9

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

MJWD/JM/B45222

2. Patent application number

(The Patent Office will fill in his part)

0015747.9

27 JUN 2000

3. Full name, address and postcode of the or of each applicant (underline all surnames)

SmithKline Beecham Biologicals s.a.
Rue de l'Institut 89, B-1330 Rixensart, , Belgium

Patents ADP number (if you know it)

6570956001

If the applicant is a corporate body, give the country/state of its incorporation

Belgian
see continuation sheet for further applicant(s)

4. Title of the invention

Vaccine

5. Name of your agent (if you have one)

CORPORATE INTELLECTUAL PROPERTY

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

SMITHKLINE BEECHAM PLC
TWO NEW HORIZONS COURT
BRENTFORD
MIDDLESEX TW8 9EP

Patents ADP number (if you know it)

7896350001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	--	-------------------------------------

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	-------------------------------------

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is named as an applicant, or
- c) any named applicant is a corporate body

See note (d)

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	1
Description	37
Claim(s)	2
Abstract	1
Drawings	9 only

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 1/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

We request the grant of a patent on the basis of this application

Signature M J W Dalton Date 27-Jun-00

12. Name and daytime telephone number of person to contact in the United Kingdom

M J W Dalton 020 8975 6348

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

CONTINUATION SHEET

Reference: MJWD/JM/B45222

Further Applicant (s)

Corixa Corporation

1124 Columbia Street

Suite 464

Seattle

WA 98104, United States of America, ,

63273510001

89 84

~~70~~ 35

VACCINE

The present invention relates to protein derivatives of a protein known as prostase, a prostate-specific serine protease, to methods for their purification and manufacture, and also to pharmaceutical compositions containing such derivatives, and to their use in medicine. In particular such derivatives find utility in cancer vaccine therapy, particularly prostate cancer vaccine therapy and diagnostic agents for prostate tumours.

In particular the derivatives of the invention include fusion proteins comprising prostase linked to an immunological or an expression enhancer fusion partner.

The present invention also provides methods for purifying the prostase derivatives and for formulating vaccines for immunotherapeutically treating prostate cancer patients and prostase-expressing tumours other than prostate tumours, prostatic hyperplasia, and prostate intraepithelial neoplasia (PIN).

Prostate cancer is the most common cancer among males, with an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasise to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality (Abbas F., Scardino P. "The Natural History of Clinical Prostate Carcinoma." *In* Cancer (1997); 80:827-833). This prevalent disease is currently the second leading cause of cancer death among men in the US.

Despite considerable research into therapies for the disease, prostate cancer remains difficult to treat. Currently, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases (Frydenberg M., Stricker P., Kaye K. "Prostate Cancer Diagnosis and Management" *The Lancet* (1997); 349:1681-1687). Several tumour-associated antigens are already known. Many of these antigens may be interesting targets for immunotherapy, but are either not fully tumour-specific or are closely related to normal proteins, and hence bear with them the risk of organ-specific auto-immunity, once targeted by a potent immune response. When an auto-immune response to non-crucial organs can be tolerated, auto-immunity to heart, intestine and other crucial organs could lead to unacceptable safety profiles. Some previously identified prostate specific proteins like

prostate specific antigen (PSA) and prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) have limited therapeutic potential and moreover are not always correlated with the presence of prostate cancer or with the level of metastasis (Pound C., Partin A., Eisenberg M. et al. "Natural History of Progression after PSA Elevation following Radical Prostatectomy." *In Jama* (1999); 281:1591-1597) (Bostwick D., Pacelli A., Blute M. et al. "Prostate Specific Membrane Antigen Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma." *In Cancer* (1998); 82:2256-2261).

The existence of tumour rejection mechanisms has been recognised since several decades. Tumour antigens, though encoded by the genome of the organism and thus theoretically not recognized by the immune system through the immune tolerance phenomenon, can occasionally induce immune responses detectable in cancer patients. This is evidenced by antibodies or T cell responses to antigens expressed by the tumour (Xue BH., Zhang Y., Sosman J. et al. "Induction of Human Cytotoxic T-Lymphocytes Specific for Prostate-Specific Antigen." *In Prostate* (1997); 30(2):73-78). When relatively weak anti-tumour effects can be observed through the administration of antibodies recognizing cell surface markers of tumour cells, induction of strong T cell responses to antigens expressed by tumour cells can lead to complete regression of established tumours in animal models (mainly murine).

It is now recognised that the expression of tumour antigens by a cell is not sufficient for *induction* of an immune response to these antigens. Initiation of a tumour rejection response requires a series of immune amplification phenomena dependent on the intervention of antigen presenting cells, responsible for delivery of a series of activation signals.

Prostase is a prostate-specific serine protease (trypsin-like), 254 amino acid-long, with a conserved serine protease catalytic triad H-D-S and a amino-terminal pre-peptide sequence, indicating a potential secretory function (P. Nelson, Lu Gan, C. Ferguson, P. Moss, R. Gelinas, L. Hood & K. Wand, "Molecular cloning and characterisation of prostase, an androgen-regulated serine protease with prostate restricted expression, *In Proc. Natl. Acad. Sci. USA* (1999) 96, 3114-3119). A putative glycosylation site has been described. The predicted structure is very similar to other known serine proteases, showing that the mature polypeptide folds into a

single domain. The mature protein is 224 amino acids-long, with one A2 epitope shown to be naturally processed.

Prostase nucleotide sequence and deduced polypeptide sequence and homologs are disclosed in Ferguson, et al. (Proc. Natl. Acad. Sci. USA 1999, 96, 3114-3119) and in International Patent Applications No. WO 98/12302 (and also the
5 3114-3119) and in International Patent Applications No. WO 98/12302 (and also the corresponding granted patent US 5,955,306), WO 98/20117 (and also the corresponding granted patents US 5,840,871 and US 5,786,148) (prostate-specific kallikrein) and WO 00/04149 (P703P).

The present invention provides prostase protein fusions based on prostase
10 protein and fragments and homologues thereof ("derivatives"). Such derivatives are suitable for use in therapeutic vaccine formulations which are suitable for the treatment of a prostate tumours.

Prostase fragments of the invention will be of at least about 10 consecutive amino acids, preferably about 20, more preferably about 50, more preferably about
15 100, more preferably about 150 contiguous amino acids selected from the amino acid sequences as shown in SEQ ID N°7 or SEQ ID N°8. More particularly fragments will retain some functional property, preferably a immunological activity, of the larger molecule set forth in SEQ ID N°7 or SEQ ID N°8, and are useful in the methods described herein (e.g. in vaccine compositions, in diagnostics, etc.). In particular the
20 fragments will be able to generate an immune response, when suitable attached to a carrier, that will recognise the protein of SEQ ID N°7 or SEQ ID N°8.

Prostase homologues will generally share substantial sequence similarity, and include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity,
25 yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:7 or SEQ ID N°8 over the entire length of SEQ ID NO:7 or SEQ ID N°8. Such polypeptides include those comprising the amino acid of SEQ ID NO:7 or SEQ ID N°8.

The prostase antigen derivative or fragments and homologues thereof may in a
30 preferred embodiment carry a mutation in the active site of the protein, to reduce substantially or preferably eliminate its protease biological activity. Preferred mutations involve replacing the Histidine and Aspartate catalytic residues of the serine protease. In a preferred embodiment, prostase contains a Histidine-Alanine

mutation at residue 71 of prostate sequence (Ferguson, et al. (Proc. Natl. Acad. Sci. USA 1999, 96, 3114-3119) which corresponds to amino acid 43 of P703PDE5 sequence (SEQ ID N°8). The mutated protein preferably has a significant decrease in the catalytic efficiency (expressed in enzymatic specific activity) of the protein as
5 compared to the non-mutated one. Preferably the reduction in the catalytic efficiency is at least by a factor of 10^3 , more preferably at least by a factor of 10^6 . The protein which has undergone a histidine alanine mutation is hereafter referred to as * (star).

In one embodiment, the present invention relates to fusions proteins, comprising the tumour-associated prostate or fragment or homologues thereof and a
10 heterologous protein or part of a protein acting as a fusion partner. The protein and the fusion partner may be chemically conjugated, but are preferably expressed as recombinant fusion proteins in a heterologous expression system.

In a preferred embodiment of the invention there is provided a prostate fusion protein or fragment or homologues thereof linked to an immunological fusion partner
15 that may assist in providing T helper epitopes. Thus the fusion partner may act through a bystander helper effect linked to secretion of activation signals by a large number of T cells specific to the foreign protein or peptide, thereby enhancing the induction of immunity to the prostate component as compared to the non-fused protein. Preferably the heterologous partner is selected to be recognizable by T cells
20 in a majority of humans.

In another embodiment, the invention provides a prostate protein or fragment or homologues thereof linked to a fusion partner that acts as an expression enhancer. Thus the fusion partner may assist in aiding in the expression of prostate in a heterologous system, allowing increased levels to be produced in an expression
25 system as compared to the native recombinant protein.

Preferably the fusion partner will be both an immunological fusion partner and an expression enhancer partner. Accordingly, the present invention in the embodiment provides fusion proteins comprising the tumour-specific prostate or a fragment thereof linked to a fusion partner. Preferably the fusion partner is acting
30 both as an immunological fusion partner and as an expression enhancer partner. Accordingly, in a preferred form of the invention, the fusion partner is the non-structural protein from influenzae virus, NS1 (hemagglutinin) or fragment thereof. Typically the N-terminal 81 amino acids are utilised, although different fragments

may be used provided they include T-helper epitopes (C. Hackett, D. Horowitz, M. Wysocka & S. Dillon, 1992, J. Gen. Virology, 73, 1339-1343). When NS1 is the immunological fusion partner it has the additional advantage in that it allows higher expression yields to be achieved. In particular, such fusions are expressed at higher yields than the native recombinant prostate proteins.

In preferred embodiments, the prostate moiety within the fusion is selected from the group comprising SEQ ID NO: 5 (Millenium WO 98/12302), SEQ ID NO: 6 (Incyte WO 98/20117), SEQ ID NO: 7 (PNAS (1999) 96, 3114-3119), and SEQ ID NO: 8 (Corixa WO 00/04149, P703PDE5 sequence). Yet in a most preferred embodiment, the fusion protein comprises the N-terminal 81 amino acids of NS1 non structural protein fused to the 5 to 226 carboxy-terminal amino acids from mutated prostate, as set forth in SEQ ID NO: 1 or SEQ ID N°3.

The proteins of the present invention are expressed in an appropriate host cell, and preferably in *E. coli*. In a preferred embodiment the proteins are expressed with an affinity tag, such as for example, a histidine tail comprising between 5 to 9 and preferably six histidine residues, most preferably at least 4 histidine residues. These are advantageous in aiding purification through for example ion metal affinity chromatography (IMAC).

The present invention also provides a nucleic acid encoding the proteins of the present invention. Such sequences can be inserted into a suitable expression vector and used for DNA/RNA vaccination or expressed in a suitable host. In additional embodiments, genetic constructs comprising one or more of the polynucleotides of the invention are introduced into cells *in vivo*. This may be achieved using any of a variety of well-known approaches. One of the preferred methods for *in vivo* delivery of one or more nucleic acid sequences involves the use of an expression vector such as a recombinant live viral or bacterial microorganism. Suitable viral expression vectors are for example poxviruses (e.g; vaccinia, fowlpox, canarypox), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), and herpesviruses (varicella zoster virus, etc). Other preferred methods for *in vivo* delivery of one or more nucleic acid sequences involves the use of a bacterial expression vector, such as *Listeria*, *Salmonella*, *Shigella* and BCG. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and

induction of immune responses. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

A DNA sequence encoding the proteins of the present invention can be synthesized using standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts *et al.* in *Biochemistry* 1985, 24, 5090-5098, by chemical synthesis, by *in vitro* enzymatic polymerization, or by PCR technology utilising for example a heat stable polymerase, or by a combination of these techniques. Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01M MgCl₂, 0.01M dithiothreitol, 1mM spermidine, 1mM ATP and 0.1mg/ml bovine serum albumin, at a temperature of 4°C to ambient, generally in a volume of 50µl or less. The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, *Nucleic Acids Research*, 1982, 10, 6243; B.S. Sproat, and W. Bannwarth, *Tetrahedron Letters*, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, *Tetrahedron Letters*, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, *Journal of the American Chemical Society*, 1981, 103, 3185; S.P. Adams *et al.*, *Journal of the American Chemical Society*, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, *Nucleic Acids Research*, 1984, 12, 4539; and H.W.D. Matthes *et al.*, *EMBO Journal*, 1984, 3, 801.

In a further embodiment of the invention is provided a method of producing a protein as described herein. The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et al.*, *Molecular Cloning - A Laboratory Manual*; Cold Spring Harbor, 1982-1989.

A
88
93

In particular, the process of the invention may preferably comprise the steps of:

- i) preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes the protein or an immunogenic derivative thereof;
- ii) transforming a host cell with said vector;
- ii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said protein; and
- iv) recovering said protein.

The term 'transforming' is used herein to mean the introduction of foreign DNA into a host cell. This can be achieved for example by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988. The term 'transformed' or 'transformant' will hereafter apply to the resulting host cell containing and expressing the foreign gene of interest. Preferably recombinant antigens of the invention are expressed in unicellular hosts, most preferably in bacterial systems, most preferably in *E. coli*.

Preferably the recombinant strategy includes cloning a gene construct encoding a NS1 fusion protein, the gene construct comprising from 5' to 3' a DNA sequence encoding NS1 joined to a DNA sequence encoding the protein of interest, into an expression vector to form a DNA fragment encoding a NS1- carboxyl-terminal P703P fusion protein. An affinity polyhistidine tail may be engineered at the carboxy-terminus of the fusion protein allowing for simplified purification through affinity chromatography.

The expression vectors are novel and also form part of the invention.

The replicable expression vectors may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment encode the desired product, such as the DNA polymer encoding the protein of the invention, or derivative thereof, under ligating conditions.

Thus, the hybrid DNA may be pre-formed or formed during the construction of the vector, as desired.

The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic but are preferably *E. coli*, yeast or CHO cells. Suitable
5 vectors include plasmids, bacteriophages, cosmids and recombinant viruses. Expression and cloning vectors preferably contain a selectable marker such that only the host cells expressing the marker will survive under selective conditions. Selection
10 genes include but are not limited to the one encoding protein that confer a resistance to ampicillin, tetracyclin or kanamycin. Expression vectors also contain control sequences which are compatible with the designated host. For example, expression
control sequences for *E. coli*, and more generally for prokaryotes, include promoters and ribosome binding sites. Promoter sequences may be naturally occurring, such as the β -lactamase (penicillinase) (Weissman 1981, *In Interferon 3* (ed. L. Gresser),
lactose (*lac*) (Chang et al. *Nature*, 1977, 198: 1056) and tryptophan (*trp*) (Goeddel et
15 al. *Nucl. Acids Res.* 1980, 8, 4057) and lambda-derived P_L promoter system. In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. This is the case for example for the *tac* synthetic hybrid promoter which is derived from sequences of the *trp* and *lac* promoters (De Boer et al., *Proc. Natl Acad Sci. USA* 1983, 80, 21-26). These systems are particularly suitable with *E. coli*.

20 Yeast compatible vectors also carry markers that allow the selection of successful transformants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Control sequences for yeast vectors include promoters for glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 1968, 7, 149), *PHO5* gene encoding acid phosphatase, *CUP1* gene, *ARG3* gene, *GAL* genes
25 promoters and synthetic promoter sequences.. Other control elements useful in yeast expression are terminators and leader sequences. The leader sequence is particularly useful since it typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. Suitable signal sequences can be encoded by genes for secreted yeast proteins such as the yeast invertase gene
30 and the α -factor gene, acid phosphatase, killer toxin, the α -mating factor gene and recently the heterologous inulinase signal sequence derived from *INU1A* gene of *Kluyveromyces marxianus*.. Suitable vectors have been developed for expression in *Pichia pastoris* and *Saccharomyces cerevisiae*.

89
94

A variety of *P. pastoris* expression vectors are available based on various inducible or constitutive promoters (Cereghino and Cregg, FEMS Microbiol. Rev. 2000,24:45-66). For the production of cytosolic and secreted proteins, the most commonly used *P. pastoris* vectors contain the very strong and tightly regulated alcohol oxidase (AOX1) promoter. The vectors also contain the *P. pastoris* histidinol dehydrogenase (HIS4) gene for selection in his4 hosts. Secretion of foreign protein require the presence of a signal sequence and the *S. cerevisiae* prepro alpha mating factor leader sequence has been widely and successfully used in Pichia expression system. Expression vectors are integrated into the *P. pastoris* genome to maximize the stability of expression strains. As in *S. cerevisiae*, cleavage of a *P. pastoris* expression vector within a sequence shared by the host genome (AOX1 or HIS4) stimulates homologous recombination events that efficiently target integration of the vector to that genomic locus. In general, a recombinant strain that contains multiple integrated copies of an expression cassette can yield more heterologous protein than single-copy strain. The most effective way to obtain high copy number transformants requires the transformation of Pichia recipient strain by the sphaeroplast technique (Cregg et al 1985, Mol.Cell.Biol. 5: 3376-3385) .

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al.* cited above.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al.* cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions depends upon the choice of the host cell to be transformed. For example, in vivo transformation using a live viral vector as the transforming agent for the polynucleotides of the invention is described above. Bacterial transformation of a host such as *E. coli* may be done by direct uptake of the polynucleotides (which may be expression vectors containing the desired sequence) after the host has been treated with a solution of CaCl_2 (Cohen *et al.*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of rubidium chloride (RbCl), MnCl_2 , potassium acetate and glycerol, and then with 3-[N-morpholino]-

propane-sulphonic acid, RbCl and glycerol. Transformation of lower eukaryotic organisms such as yeast cells in culture by direct uptake may be carried out by using the method of Hinnen et al (Proc. Natl. Acad. Sci. 1978, 75 : 1929-1933). Mammalian cells in culture may be transformed using the calcium phosphate co-precipitation of the vector DNA onto the cells (Graham & Van der Eb, Virology 1978, 52, 546). Other methods for introduction of polynucleotides into mammalian cells include dextran mediated transfection, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) into liposomes, and direct micro-injection of the polynucleotides into nuclei.

10 The invention also extends to a host cell transformed with a nucleic acid encoding the protein of the invention or a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al.* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 50°C, preferably between 25°C and 35°C, most preferably at 30°C. The incubation time may vary from a few minutes to a few hours, according to the proportion of the polypeptide in the bacterial cell, as assessed by SDS-PAGE or Western blot.

20 The product may be recovered by conventional methods according to the host cell and according to the localisation of the expression product (intracellular or secreted into the culture medium or into the cell periplasm). Thus, where the host cell is bacterial, such as *E. coli* it may, for example, be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or from cell free extracts. Where the host cell is a yeast such as *Saccharomyces cerevisiae* or *Pichia pastoris*, the product may generally be isolated from lysed cells or from the culture medium, and then further purified using conventional techniques. The specificity of the expression system may be assessed by western blot using an antibody directed against the polypeptide of interest.

30 Conventional protein isolation techniques include selective precipitation, adsorption chromatography, and affinity chromatography including a monoclonal antibody affinity column. When the proteins of the present invention are expressed

GA
90
95

with a histidine tail (His tag), they can easily be purified by affinity chromatography using an ion metal affinity chromatography column (IMAC) column.

In a preferred embodiment of the invention the proteins of the present invention is provided with an affinity tag, such as a polyhistidine tail. In such cases
5 the protein after the blocking step is preferably subjected to affinity chromatography. For those proteins with a polyhistidine tail, immobilised metal ion affinity chromatography (IMAC) may be performed. The metal ion, may be any suitable ion for example zinc, nickel, iron, magnesium or copper, but is preferably zinc or nickel. Preferably the IMAC buffer contains detergent, preferably a non-ionic detergent such
10 as Tween 80, or a zwitterionic detergent such as Empigen BB, as this may result in lower levels of endotoxin in the final product.

Further chromatographic steps include for example a Q-Sepharose step that may be operated either before or after the IMAC column. Preferably the pH is in the range of 7.5 to 10, more preferably from 7.5 to 9.5, optimally between 8 and 9, ideally
15 8.5.

The proteins of the present invention are provided either soluble in a liquid form or in a lyophilised form, which is the preferred form. It is generally expected that each human dose will comprise 1 to 1000 µg of protein, and preferably 30-300 µg.

20 The present invention also provides pharmaceutical composition comprising a protein of the present invention in a pharmaceutically acceptable excipient. A preferred vaccine composition comprises at least NS1-P703P* (SEQ ID N°1) or NS1-P703P (SEQ ID N°3). Said protein has, preferably, blocked thiol groups and is highly purified, e.g. has less than 5% host cell contamination. Such vaccine may
25 optionally contain one or more other tumour-associated antigen and derivatives. For example, suitable other associated antigen include PAP-1, PSA (prostate specific antigen), PSMA (prostate-specific membrane antigen), PSCA (Prostate Stem Cell Antigen), STEAP.

Vaccine preparation is generally described in Vaccine Design ("The subunit and adjuvant approach" (eds. Powell M.F. & Newman M.J). (1995) Plenum Press
30 New York). Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.

The proteins of the present invention are preferably adjuvanted in the vaccine formulation of the invention. Suitable adjuvants are commercially available such as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

In the formulations of the invention it is preferred that the adjuvant composition induces an immune response predominantly of the TH1 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favour the induction of cell mediated immune responses to an administered antigen. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

Accordingly, suitable adjuvants for use in eliciting a predominantly Th1-type response include, for example a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt. Other known adjuvants which preferentially induce a TH1 type immune response include CpG containing oligonucleotides. The oligonucleotides are characterised in that the CpG dinucleotide is unmethylated. Such oligonucleotides are well known and are described in, for example WO 96/02555. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science* 273:352, 1996. Another preferred adjuvant is a saponin, preferably QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred

91
46

formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

A particularly potent adjuvant formulation involving QS21 3D-MPL & tocopherol in an oil in water emulsion is described in WO 95/17210 and is a preferred formulation.

Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), Detox (Ribi, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs).

Other preferred adjuvants include adjuvant molecules of the general formula (I):



Wherein, n is 1-50, A is a bond or $-\text{C}(\text{O})-$, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12th edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

Accordingly in one embodiment of the present invention there is provided a vaccine comprising a protein of the present invention, more preferably a NS1-P703P*

adjuvanted with a monophosphoryl lipid A or derivative thereof, QS21 and tocopherol in an oil in water emulsion.

Preferably the vaccine additionally comprises a saponin, more preferably QS21. Another particular suitable adjuvant formulation including CpG and a saponin is described in WO 00/09159 and is a preferred formulation. Most preferably the saponin in that particular formulation is QS21. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumour cells. Delivery vehicles include antigen-presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumour effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumour and peri-tumoural tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumour immunity (*see* Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see* Zitvogel et al., *Nature Med.* 4:594-600, 1998).

X
92
97

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumour-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines
5 such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, lipopolysaccharide LPS, flt3 ligand and/or other compound(s) that induce
10 differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are
15 characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and
20 costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide encoding prostate tumour protein (or derivative thereof) such that the prostate tumour polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells
25 may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene
30 gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the prostate tumour polypeptide, DNA (naked or within

a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors).

5 Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

10 The present invention also provides a method for producing a vaccine formulation comprising mixing a protein of the present invention together with a pharmaceutically acceptable excipient, such as 3D-MPL.

Another aspect of the invention is the use of a protein or nucleic acid as claimed herein for the manufacture of a vaccine for immunotherapeutically treating a
15 patient suffering from prostate cancer or other prostate-associated tumours.

93
98

FIGURES LEGENDS

Figure 1: Design of the fusion protein NS1- p703* -His expressed in *E. coli*

- 5 Figure 2: Primary structure of the fusion protein NS1- p703* -His expressed in *E. coli*
(SEQ ID N°1).

Figure 3: Coding sequence of NS1₁₋₈₁-P703P*-His (SEQ ID N°2).

- 10 Figure 4: Cloning strategy to produce NS1-P703P*-His in *E. coli*

Figure 5: Plasmid map of RIT 14952

Figure 6: *E. coli* NS1-P703P*-His fermentation process

15

Figure 7: *E. coli* NS1-P703P*-His purification process

Figure 8: Immunogenicity of NS1-P703P* adjuvanted with SBAS2

- 20 Figure 9: Primary structure of the fusion protein NS1- p703 -His expressed in *E. coli*
(SEQ ID N°3).

Figure 10: Coding sequence of NS1₁₋₈₁-P703P-His (SEQ ID N°4).

25

The invention will be further described by reference to the following examples:

EXAMPLE I:

5

Preparation of the recombinant *E. coli* strain expressing the fusion protein NS1-P703P*-3-His

1. – Protein design

10

The expression strategy followed for this candidate included the design of the most appropriate primary structure for the recombinant protein that could have the best expectation for both, good level of expression and easy purification process.

Although the chance that a recombinant protein could keep its protease
15 biological activity when formulated for vaccination is really very low, the mutation of the active side was made in order to reduce substantially or preferably eliminate its proteolytical biological activity. Accordingly, the His residue at position 43 of SEQ ID N° 8, has been mutated into an Ala residue.

The design of the fusion protein NS1- p703* -His to be expressed in *E. coli* is
20 described in figure 1. This fusion contains the N-terminal (81 amino acid) of non structural protein of Influenzae virus, followed by the non processed amino acid sequence of prostate antigen (amino acids 5→226 of p703pde5 sequence described in SEQ ID N°8 containing the mutation His→Ala of the 43 residue of the protease active site followed by the His tail. The Histidine tail was added to prostase to enable
25 versatile purification of the fusion and processed protein. The length of the fusion is 313 aminoacids.

The primary structure of the resulting protein has the sequence described in figure 2. The coding sequence corresponding to the above protein is illustrated in figure 3 and was subsequently placed under the control of λ pL promoter in a *E. coli*
30 expression plasmid.



2. – The *E. Coli* expression system

For the production of NS1 the DNA encoding the 81 amino-terminal residues of NS1 (non-structural protein from influenzae virus) has been cloned into the expression vector pMG 81. This plasmid utilises signals from lambda phage DNA to drive the transcription and translation of inserted foreign genes. The vector contains the lambda PL promoter PL, operator OL and two utilisation sites (NutL and NutR) to relieve transcriptional polarity effects when N protein is provided (Gross et al., 1985. Mol. & Cell. Biol. 5:1015). Vectors containing the PL promoter, are introduced into an *E. coli* lysogenic host to stabilise the plasmid DNA. Lysogenic host strains contain replication-defective lambda phage DNA integrated into the genome (Shatzman et al., 1983; In Experimental Manipulation of Gene Expression. Inouya (ed) pp 1-14. Academic Press NY). The lambda phage DNA directs the synthesis of the cI repressor protein which binds to the OL repressor of the vector and prevents binding of RNA polymerase to the PL promoter and thereby transcription of the inserted gene. The cI gene of the expression strain AR58 contains a temperature sensitive mutation so that PL directed transcription can be regulated by temperature shift, i.e. an increase in culture temperature inactivates the repressor and synthesis of the foreign protein is initiated. This expression system allows controlled synthesis of foreign proteins especially of those that may be toxic to the cell (Shimataka & Rosenberg, 1981. Nature 292:128).

3. – The *E. Coli* strain AR58:

The AR58 lysogenic *E. coli* strain used for the production of the NS1-P703P*-His protein is a derivative of the standard NIH *E. coli* K12 strain N99 (F- su- galK2, lacZ- thr-). It contains a defective lysogenic lambda phage (galE::TN10, I Kil- cI857 DH1). The Kil- phenotype prevents the shut off of host macromolecular synthesis. The cI857 mutation confers a temperature sensitive lesion to the cI repressor. The DH1 deletion removes the lambda phage right operon and the hosts bio, uvr3, and chlA loci. The AR58 strain was generated by transduction of N99 with a P lambda phage stock previously grown on an SA500 derivative (galE::TN10, I Kil- cI857 DH1). The introduction of the defective lysogen into N99 was selected with tetracycline by virtue of the presence of a TN10 transposon coding for tetracyclin

resistance in the adjacent *galE* gene. N99 and SA500 are *E.coli* K12 strains derived from Dr. Martin Rosenberg's laboratory at the National Institutes of Health.

4. - Construction of the vector designed to express the recombinant protein NS1-P703P*-His

The starting materials were:

- 1) A cDNA plasmid received from CORIXA p703pde5 (WO 00/04149), where the putative signal sequence and a piece of the pro-peptide of P703P is missing (see fig 1) and containing the coding sequence for prostate antigen;
- 2) Vector pRIT14901 containing the long version of the PL promoter; and
- 3) Plasmid PMG81 containing the 81aa of NS₁ coding region from Influenzae virus.

The cloning strategy outlined in figure 4 included the following steps:

- a) PCR amplification of the p703 sequence with NcoI and SpeI restriction sites
The template for the PCR reaction was the cDNA plasmid received from CORIXA, the oligonucleotide sense can139 : 5'GCG CCC ATG GTT GGG GAG GAC TGC AGC CCG 3', and the oligonucleotide antisense can134 : 5'GGG ACT AGT ACT GGC CTG GAC GGT TTT CTC 3';
- b) Insertion of the amplified sequences into the commercial vector Litmus 28 (biolabs), leading to the intermediate plasmid pRIT 14949;
- c) Directed His → Ala mutagenesis of residue 43 of the p703 sequence contained in the plasmid pRIT 14949, using the sense oligonucleotide can140 : 5'CTG TCA GCC GCA GCG TGT TTC CAG 3' and the antisense oligonucleotide can141 : 5'CTG GAA ACA CGC TGC GGC TGA CAG 3', leading to the obtention of plasmid pRIT 14950;
- d) Isolation of the NcoI - SpeI fragment from the plasmid pRIT 14950;
- e) From pMG81 plasmid, purification of NS1 fragment (81aa) after digestion of the restriction sites BamHI - NcoI;
- f) Ligation of both fragments were ligated to the expression plasmid pRIT 14901 (pr PL long);

~~95~~
100

- g) Selection and characterisation of the *E. coli* AR58 strain transformants containing the plasmid pRIT14952 (see figure 5) expressing the NS1- p703 mutated -His fusion protein

5 The recombinant strain thus produces the NS1-P703P* His-tailed fusion protein of 313 amino acid residues long (see Figure 2), with the amino acids sequence described in ID No1 and the coding sequence is described in ID No2.

10 **EXAMPLE II:**

Preparation of the recombinant NS1-P703P*-3-His fusion protein

1. – Growth and induction of bacterial strain B1225 - Expression of NS1-P703P*- 15 3-His

Cells of AR58 transformed with plasmid pRIT14952 (strain B1225) were grown in a 2 L flask containing 400 ml FEC015AA medium supplemented with kanamycin sulphate (100mg/L). After a 16h of incubation at 30°C and at 200 rpm, a
20 small sample was removed from this flask for microscopic examination.

50 ml of this pre-culture was transferred into a 20-L fermentor containing 8.7 L of FEC012AF medium supplemented with kanamycin sulphate (50mg/L). The pH was adjusted to and maintained at 6.8 by addition of NH₄OH (25 % v/v), and the temperature was maintained at 30°C. The aeration rate was kept constant at 20 L/min
25 and the pO₂ was regulated at 20% of saturation by feedback control of the agitation speed. The head pressure was maintained at 0.5 bar.

This fed-batch fermentation process is based on glycerol as a carbon source. The feed solution was added at an initial rate of 0.04ml/min, and increased exponentially during the first 30 hours to limit the growth rate in order to be able to
30 keep a minimum pO₂ level of 20%.

After 30 hours, the temperature of the fermentor was rapidly increased to 39.5°C in order to induce the intracellular expression of the antigen NS1-P703P*-His. The feeding rate was maintained constant at 1.28 ml/min during the whole induction phase (18h).

Samples of broth were taken during both growth and induction phases in order to monitor bacterial growth and antigen expression. Microbiological identification and purity tests were also realised on these materials.

At the end of fermentation, the biomass reached an optical density of about 130, corresponding to a dry cell weight of about 50g/L. The final volume was approximately 10.5 L. The cells containing the antigen were directly separated from the culture medium by centrifugation at 5000g for 1 h at 4°C and the pellet was stored in plastic bags at -70°C.

2. - Extraction of the protein:

Recombinant NS1-P703P*-His protein, expressed in *E. coli* as inclusion bodies, was purified from cell homogenate using different steps (see figure 6). Briefly, frozen concentrated cells from fermentation harvest were thawed to +4°C before being resuspended in disruption buffer (phosphate 20 mM - NaCl 2M - EDTA 5 mM pH 7.5) to a final optical density (OD650) of 120. Two passes through a high-pressure homogeniser (1000 bars) disrupted the cells.

EXAMPLE III:

Purification of fusion Protein NS1-P703P*-His

a) Introduction

As said above, the recombinant protein, NS1-P703P*-His is produced in *E. coli* in the form of inclusion bodies. A major issue for the set-up of the purification method was the oxidation of the recombinant protein with itself or with host cell contaminants, likely through covalent binding with disulphide bonds. The process as developed aimed at reducing the massive oxidation phenomenon in order to have a highly purified product together with an acceptable global yield, while preserving the product ability to mount an effective immune response against the antigen of interest.

101
96

a) Description of the process

The broken cell suspension was treated on a Pallsep VMF (Vibrating Membrane Filtration) system (Pall-Filtron) equipped with 0.45 μ m membrane. The "pellet fraction" was first washed by diafiltration with 20 mM phosphate buffer pH 7.5 containing 0.5% Empigen BB detergent. The washed material was then solubilised in the same buffer containing 4M guanidine hydrochloride and 20 mM glutathione. The product was recovered through 0.45 μ m filter and the permeate was treated with 200 mM iodoacetamide to prevent oxidative re-coupling.

The carboxyamidated fraction was subjected to IMAC (Nickel-Chelating-Sepharose FF, Pharmacia). The column was first equilibrated with 20 mM Tris buffer pH 7.5 containing 4M urea, 0.5% Tween 80, and 20 mM imidazole. After the sample loading, the column was washed with the same buffer. The protein was then eluted in the previous buffer with 400 mM Imidazole.

Before continuing the anion exchange chromatography, the conductance of the IMAC-eluate was reduced to below 5 mS/cm with 20 mM Tris buffer pH 8.5 containing 4M urea and 0.5-1.0 % Tween 80. The packed bed support (Q-Sepharose FF, Pharmacia) was equilibrated with the dilution buffer. After the sample loading and a washing step with the equilibration buffer, the protein was eluted with the same buffer containing 250 mM NaCl.

The Q-Sepharose FF-eluate was then diafiltered against the appropriate storage buffer (20 mM Tris buffer pH 8.0) in a tangential flow filtration unit equipped with a 10 Kd cut-off membrane (Omega, Filtron).

Ultrafiltration retentate containing NS1-P703P*-His was sterile filtered through 0.22 μ m membrane.

The global purification yield was very high: around 3-4 g of purified material / L of homogenate (DO120).

EXAMPLE IV:**Vaccine preparation using NS1-P703P*-His protein**5 **1. – Vaccine preparation using NS1-P703P*-His protein:**

The vaccine used in these experiments is produced from a recombinant DNA, encoding a NS1-P703P*-His, expressed in *E. coli* from the strain AR58, either adjuvanted or not. As an adjuvant, the formulation comprises a mixture of 3 de -O-acylated monophosphoryl lipid A (3D-MPL) and QS21 in an oil/water emulsion. The
10 adjuvant system SBAS2 has been previously described WO 95/17210.

3D-MPL: is an immunostimulant derived from the lipopolysaccharide (LPS) of the Gram-negative bacterium *Salmonella minnesota*. MPL has been deacylated and
15 is lacking a phosphate group on the lipid A moiety. This chemical treatment dramatically reduces toxicity while preserving the immunostimulant properties (Ribi, 1986). Ribi Immunochemistry produces and supplies MPL to SB-Biologicals. Experiments performed at Smith Kline Beecham Biologicals have shown that 3D-MPL combined with various vehicles strongly enhances both the humoral and a
20 TH1 type of cellular immunity.

QS21: is a natural saponin molecule extracted from the bark of the South American tree *Quillaja saponaria* Molina. A purification technique developed to separate the individual saponines from the crude extracts of the bark, permitted the
25 isolation of the particular saponin, QS21, which is a triterpene glycoside demonstrating stronger adjuvant activity and lower toxicity as compared with the parent component. QS21 has been shown to activate MHC class I restricted CTLs to several subunit Ags, as well as to stimulate Ag specific lymphocytic proliferation (Kensil, 1992). Aquila (formally Cambridge Biotech Corporation) produces and
30 supplies QS21 to SB-Biologicals.

Experiments performed at SmithKline Beecham Biologicals have demonstrated a clear synergistic effect of combinations of MPL and QS21 in the induction of both humoral and TH1 type cellular immune responses.

10
102

The oil/water emulsion is composed an organic phase made of of 2 oils (a tocopherol and squalene), and an aqueous phase of PBS containing Tween 80 as emulsifier. The emulsion comprised 5% squalene 5% tocopherol 0.4% Tween 80 and
5 had an average particle size of 180 nm and is known as SB62 (see WO 95/17210).

Experiments performed at SmithKline Beecham Biologicals have proven that the adjunction of this O/W emulsion to 3D-MPL/QS21 (SBAS2) further increases the immunostimulant properties of the latter against various subunit antigens.

10 **2. - Preparation of emulsion SB62 (2 fold concentrate):**

Tween 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100 ml two fold concentrate emulsion 5g of DL alpha tocopherol and 5ml of squalene are vortexed to mix thoroughly. 90ml of
15 PBS/Tween solution is added and mixed thoroughly. The resulting emulsion is then passed through a syringe and finally microfluidised by using an M110S microfluidics machine. The resulting oil droplets have a size of approximately 180 nm.

3. - Lyophilisation of NS1-P703P*-His:

20

In practice, all compounds are placed in solution and sterilisation is achieved by filtration on a 0.2µm membrane. Formulations were performed the day of freeze-drying.

25 The sequence of formulation was:


H ₂ O + sucrose 15.75% + Tris 100 mM pH8 + Tween80 10%- 5 min + NS1-P703p
--

The volumes of all compounds are adjusted to have in final:

30 250-50-10 µg NS1-P703P*-His, in Tris 10 mM, tween 80 0.2%, 3.15% sucrose.

The vial was overfilled with by 1.25 x (reconstitution with 625 µl diluant, injection of 500µl).

Using the Lyovac GT6 lyophilisation apparatus purchased from Steris (Germany), the lyophilisation cycle was performed during 3 days as follows:



4. - Preparation of NS1-P703P*-His QS21/3D MPL oil in water (SBAS2)
5 formulation:

The adjuvant is formulated as a combination of MPL and QS21, in an oil/water emulsion.

- 10 1) Formulation composition (injection volume: 100μl); group 1 has received P703P*-His (20 μg) formulated in a combination of MPL and QS21, in an oil/water emulsion. Group 2 has received NS1-P703P*-His (25 μg) in a combination of MPL and QS21, in an oil/water emulsion.

15 2) Components

Components	Conc mg/ml	Buffer
P703p-His	0.513	Po4 20mM pH 7.5
NS1-P703p-his carboxy	0.846	Tris 20 mM Tween 80 0.2% pH7.5
SB62	2 x	PBS pH 6.8
MPL	8.175	H ₂ O
QS21	2	H ₂ O
Thiomersal	0.2	H ₂ O

2
103
98

3) Formulations

The formulations were prepared extemporaneously on the day of injection.

The formulations containing 3D-MPL and QS21 in an oil/water emulsion (SBAS2B formulations - Groups 2 and 3) were performed as follows: P703p (20µg) (group 2) and NS1-P703P*-His (25µg) (group 3) were diluted in 10-fold concentrated PBS pH 6.8 and H₂O before consecutive addition of SB62 (50µl), MPL (20µg), QS21 (20µg) and 1 µg/ml thiomersal as preservative at 5 min intervals. All incubations were carried out at room temperature with agitation.

The non-adjuvanted formulations (Groups 4 and 5) were performed as follows: P703p (20µg) (group 4) and NS1-P703P*-His (25µg) (group 5) were diluted in 1.5 M NaCl and H₂O before addition of 1 µg/ml thiomersal as preservative at 5 min intervals. All incubations were carried out at room temperature with agitation.

The final vaccine is obtained after reconstitution of the lyophilised NS1-P703P*-His preparation with the adjuvant or with PBS alone.

The adjuvant controls without antigen were prepared by replacing the protein by PBS.

20 EXAMPLE V:

Immunogenicity using NS1-P703P*-His protein

1. - Immunogenicity of NS1-P703P*-His in mice

25

The aim of the experiment was to characterise the immune response induced in mice by vaccination with the purified recombinant mutated NS1-p703*-His molecule produced in *E coli*, in the presence or the absence of an adjuvant.

30

a) - Immunization protocol:

Groups of 10 immunocompetent Balb/c mice, 6 to 8 weeks old mice, were vaccinated twice, intramuscularly, at 2 weeks interval with 25 µg of mutated NS1-P703 formulated or not in SB AS02B (50µl SB62 / 10µg MPL / 10µg QS21).

14 days after the second injection, blood was taken and the sera were tested for the presence of anti-P703 antibodies.

b) – Total IgG Antibody response:

5 The anti P703 antibody response has been assessed in the sera of the mice 14 days after the latest vaccination. This has been done by ELISA using NS1-P703P* as coating antigen.

E coli extracts were used to check for the possible presence of antibodies against host contaminants.

10

c) – Results:

The results show that 1) a higher immune response (IgG1) is induced by NS1-P703P* as evidenced in the sera of mice injected with the NS1-P703P* protein alone as compared to the sera of normal control mice; 2) high antibody titers are found in
15 animals receiving the NS1-P703P* molecule formulated in the AS02B adjuvant.

The isotypic profile of the NS1-p703p specific IgG response has also been measured. As shown in Figure 8, IgG1 were detected when mice received the NS1-P703P* protein alone, however the isotypic profile was pushed towards a TH1 response (more IgG2a) by the presence of the AS02 adjuvant.

20

EXAMPLE VI:

1. – NS1-P703P-His

25

In an analogous fashion NS1-P703P-His was prepared. The amino acid and DNA sequences are depicted in SEQUENCE ID Nos. 3 and 4.

Briefly, the strategy to express a NS1-P703P-His fusion protein in *E.coli* included the following steps:

- 30 a) As a starting materiel, the same starting material as described in Example I (amino acids 5→226 of p703pde5 sequence described in SEQ ID N°8);
- b) PCR amplification to flank the p703 unmutated sequence cloning restriction sites;
- c) Insertion in a PMG81 vector (promoter pL long) containing the NS1 gene;

~~8~~
104
99

- d) Transformation of the recipient strain AR58 or AR120
- e) Selection of recombinant strain.

5 The resulting protein can be purified in an analogous manner to the NS1-P703P*-His mutated protein. The primary structure of the resulting protein has the sequence described in figure 9. The coding sequence corresponding to the above protein is illustrated in figure 10.

10

SEQUENCE LISTING

5 <110> Cabezon Teresa
 Dillon Davin

 <120> Prostase fusion

10 <130> B45222

 <160> 8

15 <170> FastSEQ for Windows Version 3.0

 <210> 1
 <211> 312
 <212> PRT

20 <213> Human

 <400> 1

	Met	Asp	Pro	Asn	Thr	Val	Ser	Ser	Phe	Gln	Val	Asp	Cys	Phe	Leu	Trp	
	1				5					10					15		
25	His	Val	Arg	Lys	Arg	Val	Ala	Asp	Gln	Glu	Leu	Gly	Asp	Ala	Pro	Phe	
				20					25					30			
	Leu	Asp	Arg	Leu	Arg	Arg	Asp	Gln	Lys	Ser	Leu	Arg	Gly	Arg	Gly	Ser	
				35				40					45				
	Thr	Leu	Gly	Leu	Asp	Ile	Glu	Thr	Ala	Thr	Arg	Ala	Gly	Lys	Gln	Ile	
30		50					55					60					
	Val	Glu	Arg	Ile	Leu	Lys	Glu	Glu	Ser	Asp	Glu	Ala	Leu	Lys	Met	Thr	
	65					70					75					80	
	Met	Val	Gly	Glu	Asp	Cys	Ser	Pro	His	Ser	Gln	Pro	Trp	Gln	Ala	Ala	
					85					90					95		
35	Leu	Val	Met	Glu	Asn	Glu	Leu	Phe	Cys	Ser	Gly	Val	Leu	Val	His	Pro	
				100					105					110			
	Gln	Trp	Val	Leu	Ser	Ala	Ala	Ala	Cys	Phe	Gln	Asn	Ser	Tyr	Thr	Ile	
				115				120					125				
	Gly	Leu	Gly	Leu	His	Ser	Leu	Glu	Ala	Asp	Gln	Glu	Pro	Gly	Ser	Gln	
40		130					135					140					
	Met	Val	Glu	Ala	Ser	Leu	Ser	Val	Arg	His	Pro	Glu	Tyr	Asn	Arg	Pro	
	145					150					155					160	
	Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile	Lys	Leu	Asp	Glu	Ser	Val	Ser	
				165						170					175		
45	Glu	Ser	Asp	Thr	Ile	Arg	Ser	Ile	Ser	Ile	Ala	Ser	Gln	Cys	Pro	Thr	
				180					185					190			
	Ala	Gly	Asn	Ser	Cys	Leu	Val	Ser	Gly	Trp	Gly	Leu	Leu	Ala	Asn	Gly	
			195					200					205				
	Arg	Met	Pro	Thr	Val	Leu	Gln	Cys	Val	Asn	Val	Ser	Val	Val	Ser	Glu	
50		210					215					220					
	Glu	Val	Cys	Ser	Lys	Leu	Tyr	Asp	Pro	Leu	Tyr	His	Pro	Ser	Met	Phe	
	225					230					235					240	

~~105~~
100

15

25

50

- 31 -

<212> PRT

<213> Human

<400> 3

5 Met Asp Pro Asn Thr Val Ser Ser Phe Gln Val Asp Cys Phe Leu Trp
 1 5 10 15
 His Val Arg Lys Arg Val Ala Asp Gln Glu Leu Gly Asp Ala Pro Phe
 20 25 30
 Leu Asp Arg Leu Arg Arg Asp Gln Lys Ser Leu Arg Gly Arg Gly Ser
 10 35 40 45
 Thr Leu Gly Leu Asp Ile Glu Thr Ala Thr Arg Ala Gly Lys Gln Ile
 50 55 60
 Val Glu Arg Ile Leu Lys Glu Glu Ser Asp Glu Ala Leu Lys Met Thr
 65 70 75 80
 15 Met Val Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala
 85 90 95
 Leu Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro
 100 105 110
 Gln Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile
 20 115 120 125
 Gly Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln
 130 135 140
 Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
 145 150 155 160
 25 Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
 165 170 175
 Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
 180 185 190
 Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 30 195 200 205
 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
 210 215 220
 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe
 225 230 235 240
 35 Cys Ala Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser
 245 250 255
 Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe
 260 265 270
 Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn
 40 275 280 285
 Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser Thr
 290 295 300
 Ser Gly His His His His His His
 305 310

<210> 4

<211> 939

<212> DNA

<213> Human

<400> 4



atggatccaa acactgtgtc aagctttcag gtagattgct ttctttggca tgtccgcaaa
 60
 cgagttgcag accaagaact aggtgatgcc ccattccttg atcgggttcg ccgagatcag
 120
 5 aaatccctaa gaggaagggg cagcaccctc ggtctggaca tcgagacagc cacacgtgct
 180
 ggaaagcaga tagtggagcg gattctgaaa gaagaatccg atgaggcact taaaatgacc
 240
 atggttgggg aggactgcag cccgcactcg cagccctggc aggcggcact ggtcatggaa
 10 300
 aacgaattgt tctgctcggg cgtcctgggtg catccgcagt ggggtgctgtc agccgcacac
 360
 tgtttccaga actcctacac catcgggctg ggcctgcaca gtcttgaggc cgaccaagag
 420
 15 ccagggagcc agatgggtgga ggccagcctc tccgtacggc acccagagta caacagaccc
 480
 ttgctcgcta acgacctcat gctcatcaag ttggacgaat ccgtgtccga gtctgacacc
 540
 atccggagca tcagcattgc ttcgcagtgc cctaccgcgg ggaactcttg cctcgtttct
 600
 ggctgggggtc tgctggcgaa cggcagaatg cctaccgtgc tgcagtgcgt gaacgtgtcg
 660
 gtggtgtctg aggaggtctg cagtaagctc tatgaccgcg tgtaccaccc cagcatgttc
 720
 25 tgcgcgggcy gagggcaaga ccagaaggac tcctgcaacg gtgactctgg ggggccccctg
 780
 atctgcaacg ggtacttgca gggccttggtg tctttcggaa aagccccgtg tggccaagtt
 840
 ggcgtgccag gtgtctacac caacctctgc aaattcactg agtggataga gaaaaccgtc
 30 900
 caggccagta ctagtggcca ccatcaccat caccattaa
 939

<210> 5

<211> 232

<212> PRT

<213> Human

<400> 5

40 Asn Ser Ala Arg Ala His Ser Gln Pro Trp Gln Ala Ala Leu Val Met
 1 5 10 15
 Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
 20 25 30
 Leu Ser Ala Ala His Cys Phe Gln Lys Xaa Val Gln Ser Ser Tyr Thr
 35 40 45
 45 Ile Gly Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser
 50 55 60
 Gln Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg
 65 70 75 80
 50 Pro Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val
 85 90 95
 Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro

Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys Phe Thr Glu Trp
 225 230 235 240
 Ile Glu Lys Thr Val Gln Ala Ser
 245

5

<210> 7
 <211> 254
 <212> PRT
 <213> Human

10

<400> 7

15

Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
 1 5 10 15
 Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
 20 25 30
 Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
 35 40 45
 Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
 50 55 60
 Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
 65 70 75 80
 Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
 85 90 95
 Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
 100 105 110
 Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
 115 120 125
 Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
 130 135 140
 Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
 145 150 155 160
 Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
 165 170 175
 Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
 180 185 190
 Ala Gly Gly Gly His Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly
 195 200 205
 Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
 210 215 220
 Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
 225 230 235 240
 Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
 245 250

45

<210> 8
 <211> 226
 <212> PRT
 <213> Human

50

<400> 8

Glu Phe His Cys Val Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp
 1 5 10 15

	Gln	Ala	Ala	Leu	Val	Met	Glu	Asn	Glu	Leu	Phe	Cys	Ser	Gly	Val	Leu
				20					25					30		
	Val	His	Pro	Gln	Trp	Val	Leu	Ser	Ala	Ala	His	Cys	Phe	Gln	Asn	Ser
			35					40					45			
5	Tyr	Thr	Ile	Gly	Leu	Gly	Leu	His	Ser	Leu	Glu	Ala	Asp	Gln	Glu	Pro
		50				55						60				
	Gly	Ser	Gln	Met	Val	Glu	Ala	Ser	Leu	Ser	Val	Arg	His	Pro	Glu	Tyr
	65					70					75				80	
	Asn	Arg	Pro	Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile	Lys	Leu	Asp	Glu
10					85					90					95	
	Ser	Val	Ser	Glu	Ser	Asp	Thr	Ile	Arg	Ser	Ile	Ser	Ile	Ala	Ser	Gln
				100					105					110		
	Cys	Pro	Thr	Ala	Gly	Asn	Ser	Cys	Leu	Val	Ser	Gly	Trp	Gly	Leu	Leu
			115					120					125			
15	Ala	Asn	Gly	Arg	Met	Pro	Thr	Val	Leu	Gln	Cys	Val	Asn	Val	Ser	Val
		130					135					140				
	Val	Ser	Glu	Glu	Val	Cys	Ser	Lys	Leu	Tyr	Asp	Pro	Leu	Tyr	His	Pro
	145					150					155				160	
	Ser	Met	Phe	Cys	Ala	Gly	Gly	Gly	Gln	Asp	Gln	Lys	Asp	Ser	Cys	Asn
20					165					170					175	
	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Ile	Cys	Asn	Gly	Tyr	Leu	Gln	Gly	Leu
				180					185					190		
	Val	Ser	Phe	Gly	Lys	Ala	Pro	Cys	Gly	Gln	Val	Gly	Val	Pro	Gly	Val
			195					200					205			
25	Tyr	Thr	Asn	Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln
		210					215						220			
	Ala	Ser														
	225															

30

A
103
T08

REFERENCES:

- Abbas F., Scardino P. "The Natural History of Clinical Prostate Carcinoma." *Cancer* 80:827-833 (1997)
5
- Bostwick D., Pacelli A., Blute M. et al. "Prostate Specific Membrane Antigen "Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma." *Cancer* 82:2256-2261 (1998)
- Frydenberg M., Stricker P., Kaye K. "Prostate Cancer Diagnosis and
10 Management." *The Lancet* 349:1681-1687 (1997)
- C. Hackett, D. Horowitz, M. Wysocka & S. Dillon, *J. Gen. Virology*, 73, 1339-1343 (1992)
- Kensil C.R., Soltysik S., Patel U., et al. in: Channock R.M. , Ginsburg H.S., Brown F., et al., (eds.), *Vaccines 92*, (Cold Spring Harbor Laboratory Press, Cold
15 Spring Harbor, N.Y.), 36-40: (1992)
- Nelson P., Lu Gan, Ferguson C., Moss P., Gelinas R., Hood L. & Wand K., "Molecular cloning and characterisation of prostate, an androgen-regulated serin protease with prostate restricted expression", *Proc. Natl. Acad. Sci. USA* 96, 3114-3119 (1999)
- 20 - Pound C., Partin A., Eisenberg M. et al. "Natural History of Progression after PSA Elevation following Radical Prostatectomy." *Jama* 281:1591-1597 (1999)
- Ribí E., et al. in: Levine L., Bonventre P.F., Morello J., et al. (eds), American Society for Microbiology, Washington DC, *Microbiology 1986*, 9-13; (1986)
- Xue BH., Zhang Y., Sosman J. et al. "Induction of Human Cytotoxic T-
25 Lymphocytes Specific for Prostate-Specific Antigen." *Prostate* 30(2):73-78 (1997)

CLAIMS:

1. A prostase protein or a derivative thereof linked to a fusion partner.
2. A protein as claimed in claim 1 wherein the prostase antigen is selected from the
5 group consisting of SEQ ID N° 5, SEQ ID N° 6, SEQ ID N° 7, and SEQ ID N° 8.
3. A protein as claimed in claim 1 or 2 wherein the fusion partner is an immunological fusion partner or an expression enhancer fusion partner.
4. A protein as claimed in claim 1 to 3 wherein the fusion partner is NS1 protein from influenza or a fragment thereof.
- 10 5. An antigen as claimed in any of claims 1 to 4 wherein the fusion protein further comprises an affinity tag.
6. A nucleic acid sequence encoding a protein as claimed in any of claims 1 to 5.
7. An expression vector containing a nucleic acid of claim 6.
8. A host cell transformed with a nucleic acid sequence of claim 6 or with a vector as
15 claimed in claim 7.
9. A vaccine containing a protein as claimed in any of claims 1 to 5 or a nucleic acid as claimed in claim 6.
10. A vaccine as claimed in claim 9 additionally comprising an adjuvant, and/or immunostimulatory cytokine or chemokine.
- 20 11. A vaccine as claimed in claim 9 or 10 wherein the protein is presented in an oil in water or a water in oil emulsion vehicle.
12. A vaccine as claimed in claim 10 or 11 wherein the adjuvant comprises 3D-MPL, QS21, a CpG oligonucleotide or a polyethylene ether or ester.
13. A vaccine as claimed in any of claims 9 to 12 additionally comprising one or more
25 other antigens.
14. A vaccine as claimed herein for use in medicine.


10/1
10/9

15. Use of a protein or nucleic acid as claimed herein for the manufacture of a vaccine for immunotherapeutically treating a patient suffering from prostate cancer or other prostate-associated tumours.
- 5 16. A process for the production of a protein as claimed in any of claims 1 to 5 comprising transforming a host cell with a nucleic acid sequence of claim 6, expressing said sequence and isolating the desired product.
- 10 17. A process for the production of a vaccine, comprising the steps of purifying a prostate protein or a derivative thereof, by the process of claim 16 and admixing the resulting protein as claimed herein with a suitable adjuvant, diluent or other pharmaceutically acceptable excipient.
18. A method of treating patients susceptible to or suffering from prostate-cancer comprising administering to said patients a pharmaceutically active amount of the vaccine according to claims 9 to 14.

ABSTRACT


Vaccine

5

The present invention relates to novel proteins and to their production, from the
prostase family. In particular, the invention pertains to a prostase protein or fragment
thereof fused to an immunological fusion partner, such as NS1. Such antigens may be
formulated to provide vaccines for the treatment of prostate tumours. Novel methods
10 for purifying prostase protein and homologues are also provided.

~~NS1~~
H0
105

Figure 1: Design of the fusion protein NS1- p703* -His expressed in *E. coli*.



5

Figure 2: Primary sequence of the NS1- p703* -His protein expressed in *E. coli*

10

MDPNTVSSFQVDCFLWHVRKRVADQELGDAPFLDRLRRDQ 40
 KSLRGRGSTLGLDIETATRAGKQIVERILKEESDEALKMT 80
 MVGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAA 120
 CFQNSYITIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRP 160
 15 LLANDMLIKLDESVSSESDTIRSIASQCPTAGNSCLVS 200
 GWGLLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMF 240
 CAGGGQDQKDSCNGDSGGPLICNGYLQGLVSFGKAPCGQV 280
 GVPGVYTNLCKFTEWIEKTVQASTSGHHHHHH. 312

20

Figure 3: Nucleotide sequence of NS₁-p703 mutated-His (pRIT14952)

ATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCT 40
 TTCTTTGGCATGTCCGCAAACGAGTTGCAGACCAAGAACT 80
 AGGTGATGCCCCATTCCTTGATCGGCTTCGCCGAGATCAG 120
 25 AAATCCCTAAGAGGAAGGGGCAGCACcCTcGGTCTGGACA 160
 TCGAGACAGCCACACGTGCTGGAAAGCAGATAGtGGAGCG 200
 GAttctGAAAGAAGAATCCGATGAGGCACTTAAATGACC 240
 atgGTTGGGGAGGACTGCAGCCCGCACTCGCAGCCCTGGC 280
 AGGCGGCACTGGTCATGGAAAACGAATTGTTCTGCTCGGG 320
 30 CGTCCTGGTGCATCCGCAGTGGGTGCTGTCAGCCGCAgcg 360

~~AP~~
711
106

TGTTTCCAGAACTCCTACACCATCGGGCTGGGCCTGCACA 400
GTCTTGAGGCCGACCAAGAGCCAGGGAGCCAGATGGTGGA 440
GGCCAGCCTCTCCGTACGGCACCCAGAGTACAACAGACCC 480
TTGCTCGCTAACGACCTCATGCTCATCAAGTTGGACGAAT 520
5 CCGTGTCCGAGTCTGACACCATCCGGAGCATCAGCATTGC 560
TTCGCAGTGCCCTACCGCGGGGAACTCTTGCCCTCGTTTCT 600
GGCTGGGGTCTGCTGGCGAACGGCAGAATGCCTACCGTGC 640
TGCAGTGCGTGAACGTGTCGGTGGTGTCTGAGGAGGTCTG 680
CAGTAAGCTCTATGACCCGCTGTACCACCCCAGCATGTTC 720
10 TGCGCCGGCGGAGGGCAAGACCAGAAGGACTCCTGCAACG 760
GTGACTCTGGGGGGCCCTGATCTGCAACGGGTACTTGCA 800
GGGCCTTGTGTCTTTCGGAAAAGCCCCGTGTGGCCAAGTT 840
GGCGTGCCAGGTGTCTACACCAACCTCTGCAAATTCCTG 880
AGTGGATAGAGAAAACCGTCCAGGCCAGTactagtggcca 920
15 ccatcaccatcaccattaa 939

Handwritten notes:
 H2
 107

Figure 4: cloning strategy to produce NS1-P703P*-His in *E. coli*





Figure 5: Plasmid map of pRIT 14952



5

AK
113¹⁰⁸

AA

7/14

09

Figure 6: E. coli NS1-P703P*-His fermentation process

5

10

15


20

25

30

35

40



AA
115
110

Figure 7 : E. coli NS1-P703P*-His purification process




Figure 8: Immunogenicity of NS1-P703P* adjuvanted with SBAS2




Figure 9: Primary sequence of the NS1- p703 -His protein expressed in *E. coli*

MDPNTVSSFQVDCFLWHVRKRVADQELGDAPFLDRLRRDQ 40
 KSLRGRGSTLGLDIETATRAGKQIVERILKEESDEALKMT 80
 5 MVGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAH 120
 CFQNSYITIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRP 160
 LLANDLMLIKLDESSES DTIRSIASQCPTAGNSCLVS 200
 GWGLLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMF 240
 CAGGGQDQKDCNGDSGGPLICNGYLQGLVSFGKAPCGQV 280
 10 GVPGVYTNLCKFTEWIEKTVQASTSGHHHHHH. 313

Figure 10: Nucleotide sequence of NS₁-p703 -His

15 ATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCT 40
 TTCTTTGGCATGTCCGCAAACGAGTTGCAGACCAAGAACT 80
 AGGTGATGCCCCATTCTTGATCGGCTTCGCCGAGATCAG 120
 AAATCCCTAAGAGGAAGGGGCAGCACcCTcGGTCTGGACA 160
 TCGAGACAGCCACACGTGCTGGAAAGCAGATAGtGGAGCG 200
 20 GAttctGAAAGAAGAATCCGATGAGGCACTTAAAATGACC 240
 atgGTTGGGGAGGACTGCAGCCCGCACTCGCAGCCCTGGC 280
 AGGCGGCACTGGTCATGGAAAACGAATTGTTCTGCTCGGG 320
 CGTCCTGGTGCATCCGCAGTGGGTGCTGTCAGCCGCAcac 360
 TGTTTCCAGAACTCCTACACCATCGGGCTGGGCCTGCACA 400
 25 GTCTTGAGGCCGACCAAGAGCCAGGGAGCCAGATGGTGGA 440
 GGCCAGCCTCTCCGTACGGCACCCAGAGTACAACAGACCC 480
 TTGCTCGCTAACGACCTCATGCTCATCAAGTTGGACGAAT 520
 CCGTGTCCGAGTCTGACACCATCCGGAGCATCAGCATTGC 560
 TTCGCAGTGCCCTACCGCGGGGAACTCTTGCCTCGTTTCT 600
 30 GGCTGGGGTCTGCTGGCGAACGGCAGAATGCCTACCGTGC 640
 TGCAGTGCCTGAACGTGTCGGTGGTGTCTGAGGAGGTCTG 680
 CAGTAAGCTCTATGACCCGCTGTACCACCCAGCATGTTC 720
 TGCGCCGGCGGAGGGCAAGACCAGAAGGACTCCTGCAACG 760
 GTGACTCTGGGGGGCCCTGATCTGCAACGGGTACTTGCA 800

B45222

GGGCCTTGTGTCTTTCGGAAAAGCCCCGTGTGGCCAAGTT 840
GGCGTGCCAGGTGTCTACACCAACCTCTGCAAATTCCTG 880
AGTGGATAGAGAAAACCGTCCAGGCCAGTactagtggcca 920
ccatcaccatcaccattaa 939

5

Handwritten signature and numbers: 118, 113



129 114

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

Logo de la marca de la fundación




Logo y nombre de LA OFICINA DE PATENTES
Patentes – Diseños – Marcas de Fábrica – Derechos de Autor



INVESTOR IN PEOPLE

Logo y nombre de INVERSIONISTA EN LA GENTE



Hay un ojete perforado con cinta violeta que ata el documento y que le da la vuelta y se encuentra sellado por medio de un sello seco, colocado sobre plástico rojo que dice así:

LA OFICINA DE PATENTES y en el centro tiene un escudo de armas

20/11/15

Yo, el suscrito, siendo un oficial debidamente autorizado de acuerdo con la Sección 74 (1) y (4) de la Ley de Deregulación y Contrataciones de 1994, para firmar y expedir certificados a nombre del Inspector-General, por medio de la presente Certifico que lo anexado a la presente es una copia verdadera de los documentos tal como se llenaron originalmente en relación con la solicitud de patente aquí identificada.

De acuerdo con la Ley de Patentes (Re-Registro de Compañías) de 1982, si una compañía nombrada en este certificado y en cualquiera de los documentos que se acompañan tiene un re-registrado bajo la Ley de Compañías de 1980, con el mismo nombre con el cual fue registrado inmediatamente antes que el re-registro quedara para la sustitución o la inclusión como, la última parte del nombre de las palabras "public limited company" o sus equivalentes en Welsh, las referencias al nombre de la compañía en este certificado y cualesquiera documentos que lo acompañen deberán ser tratados como referencias sobre el nombre con el cual está re-registrado así.

De acuerdo con las reglas, las palabras "Public Limited Company" puede reemplazarse por p.l.c, plc, P.L.C. o PLC.

121
116

El Re-registro bajo la Ley de Compañías no constituye una entidad legal nueva, sino que meramente sujeta a la compañía a ciertas leyes adicionales a la compañía.

(Firmado) Andrew Jersey

Fecha: 2 de Agosto del 2000

Una Agencia Ejecutiva del Departamento de Comercio e Industria.

922
117

LA OFICINA DE PATENTES

(sello ovalado en la mitad superior proveniente de la oficina de patentes de Londres)

fechado junio 27, 2000

Ley de Patentes de 1977

(Regulación 16)

Solicitud para Otorgamiento de Una Patente

(Véase las notas de la parte trasera de este formulario. Usted también puede conseguir un folleto explicatorio en la Oficina de Patentes para ayudarle a llenar este formulario).

28JUN00 E548473-1D02029

P01/77000.00-0015747.9

La Oficina de Patentes

Cardiff Road

Newport

Gwent NP9 1RH

1.-Su Referencia:

MJWD/JM/B45222

2.-Número de Solicitud de Patente:

0015747.9

(La oficina de patentes llenará esta parte)

Junio 27 del 2000

3.-Nombre completo, dirección y código postal de cada uno de (l) (los) solicitantes.

SmithKline Beechman Biologicals s.a

Rue de L'Institut 89, B-1330

(subraye los apellidos)

Rixensart, Bélgica

Número ADP de la Patente (si lo sabe):

6570956001

Si el solicitante es una corporación, dé el País/Estado en donde se incorporó.

Bélgica

(Véase la hoja a continuación para los otros solicitantes)

4.-Título de la Invención:

Vacuna

5.-Nombre de su Agente (si lo tiene)

CORPORATE INTELLECTUAL
PROPERTY

“Dirección para el Servicio” dentro del Reino Unido a la cual se debe enviar toda la correspondencia:

(incluyendo el código postal)

SMITHKLINE BEECHMAN PLC
TWO NEW HORIZONS COURT
BRENTFORD
MIDDLESEX TW8 9EP

Número ADP de las Patentes (Si lo conoce):

7896350001

6.- Si usted esta declarando prioridad de una o más solicitudes de patentes anteriores, dé el país y la fecha de presentación de la o de cada una de estas solicitudes anteriores y (si usted lo sabe) el o los números de solicitud.

País # de Solicitud (si lo conoce)

Fecha de Presentación(día/mes/año)

7.-Si esta solicitud está dividida o de cualquier otra forma se deriva de una solicitud anterior en el Reino Unido, dé el número y fecha de la presentación de la solicitud anterior

Número de la anterior Solicitud
(si lo conoce)

Fecha de Registro
(Día, Mes, año)

8.-Se necesita una declaración de invención y el derecho a otorgar de una patente para apoyar esta solicitud?. (Responda sí, en caso de:)

- a) Cualquier solicitante nombrado en la parte 3 que no es un inventor,
- b) Hay un inventor que se nombra como un solicitante,
- c) Cualquier solicitante nombrado es un

723
118

cuerpo corporativo
Ver nota (d)

~~128~~
124
119

En la parte posterior encontramos lo siguiente:

9.-Ingrese el número de hojas para cualquiera de los asuntos (items) que siguen, los cuales usted llena junto con este formulario. No cuente las copias del mismo documento.

Hojas de Continuación de este formulario	1
Descripciones	37
Reivindicaciones	2
Resúmenes	1
Dibujos	9 solamente

10.- Si usted está llenando también cualquiera de los siguientes documentos: (declare cuántos para cada item)

Documentos de Prioridad
Traducción de Documentos de
Prioridad
Declaración de Invención y de
derechos para otorgar de una
Patente (<i>formulario de patentes</i>
<i>1/77</i>)
Solicitud para un examen

125 120

preliminar y búsqueda (*formulario
de patentes 9/77*)

Solicitud para un examen sustancial
(formularios de patentes (10/77)

Cualesquiera otros documentos (por
favor especificar)

11 Nosotros solicitamos el
otorgamiento de una patente
basados en esta solicitud.

(Firmado) M. J. W. Dalton

Fecha: 27 de Junio del 2000

12. Nombre y número de teléfono M.J.W. Dalton 020 8975 6348
diurno de la persona a contactar en
el Reino Unido

Advertencia:

Después de haber registrado una solicitud de Patente, el Inspector de la Oficina de Patentes considerará si la publicación o comunicación de la invención se debe prohibir o restringir de acuerdo con la Sección 22 de la Ley de Patentes de 1977. Usted será informado si resulta necesario prohibir o restringir su invención de esta forma. Más aún, si usted vive en el Reino Unido, la Sección 23 de la Ley de Patentes de 1977 le impide a usted solicitar una patente en el extranjero sin conseguir primero un permiso por escrito, a menos que se haya registrado por lo menos seis

semanas antes en el Reino Unido una solicitud de Patente para la misma invención y no se ha dado cualquier directiva prohibiendo su publicación o comunicación o tal directiva se ha revocado.

26
121

NOTAS:

- a) Si usted necesita ayuda para llenar este formulario o usted tiene preguntas, sírvase contactar la Oficina de Patentes en el teléfono 0645 500505.
- b) Escriba sus respuestas en letras mayúsculas usando tinta negra o usted las puede escribir a máquina.
- c) Si no hay espacio suficiente para colocar todos los detalles de importancia en alguna parte de este formulario, sírvase continuar en una hoja de papel por separado y escriba: "véase hoja de continuación" en la parte o partes pertinentes. Cualquier hoja de continuación debe adjuntarse a este formulario.
- d) Si usted ha respondido "Sí" se necesita llenar el formulario 7/77.
- e) Para detalles sobre los honorarios y las formas de pagarlo, sírvase contactar a la Oficina de Patentes.

En la siguiente hoja encontramos lo siguiente:

HOJA DE CONTINUACIÓN

Referencia: MJWD/JM/B45222

Otros Solicitantes:

Corixa Corporation

1124 Columbia Street

Suite 464

Seattle,

(WA) 98104, Estados Unidos de América


63273510001

~~U~~
127
122

REIVINDICACIONES:

- 1.- Una proteína prostasa o un derivado del mismo enlazado a un compañero de fusión.
- 2.- Una proteína que está reivindicada como reivindicación 1, en donde el antígeno prostático se selecciona a partir del grupo que consta de SEQ ID # 5, SEQ ID # 6 , SEQ ID # 7, y SEQ ID # 8.
- 3.- Una proteína que está reivindicada como reivindicación 1 y 2, en donde el compañero de fusión es un compañero de fusión inmunológico o un mejorador de la expresión de compañero de fusión .
- 4.- Una proteína que está reivindicada como reivindicación 1 a 3, en donde el compañero de fusión es una proteína NSI de la gripa o un fragmento de la misma.
- 5.- Un antígeno que está reivindicado en cualquiera de las reivindicaciones 1 a 4, en donde la proteína de fusión comprende además una etiqueta de afinidad.
- 6.- Una secuencia de ácido nucleico codificando una proteína como se reivindica en cualquiera de las reivindicaciones 1 a 5.

123

- 
- 7.- Un vector de expresión que contiene un ácido nucleico de la reivindicación 6.
- 8.- Una célula anfitriona transformada por una secuencia de un ácido nucleico de la reivindicación 6 o por un vector como se reivindica en la reivindicación 7.
- 9.- Una vacuna que contiene una proteína tal como se reivindica en la reivindicación 1 a 5 o un ácido nucleico tal como se reivindica en la reivindicación 6.
- 10.- Una vacuna tal como se reivindicó en la reivindicación 9, comprendiendo adicionalmente un adyuvante y/o citokina o kemokina inmunoestimuladora.
- 11.- Una vacuna tal como se reivindicó en las reivindicaciones 9 o 10, en donde las proteínas se presentan en un aceite en agua o en agua en vehículo con una emulsión aceitosa.
- 12.- Una vacuna tal como se reivindicó en las reivindicaciones 10 u 11, en donde el adyuvante comprende 3D-MPL, QS21, un oligonucleótido CpG o un eter o ester de polietileno.
- 13.- Una vacuna tal como se reivindicó en las reivindicaciones 9 a 12, comprendiendo adicionalmente uno o más antígenos adicionales.

14.- Una vacuna tal como se reivindicó aquí para uso en medicina.

15.- Uso de una proteína o ácido nucleico tal como se reivindicó aquí para la fabricación de una vacuna para el tratamiento inmunoterapéutico de un paciente que sufre de cáncer prostático o de cánceres asociados con la prostasa.

16.- Un proceso para la producción de proteína tal como se reivindicó en cualquiera de las reivindicaciones 1 a 5, que comprende la transformación de una célula anfitriona con una secuencia de ácido nucleico de la reivindicación 6, expresando dicha secuencia y aislando el producto deseado.

17.- Un proceso para la producción de una vacuna, que comprende los pasos de purificar una proteína de prostasa o un derivado de la misma, por medio del proceso de la reivindicación 16 y admezclando la proteína resultante tal como se reivindica aquí con un adyuvante adecuado, un diluyente u otro excipiente aceptable desde el punto de vista farmacéutico.

18.- Un método para tratar pacientes susceptibles de o que sufran de cáncer prostático, administrándole a dichos pacientes una cantidad activa farmacéuticamente hablando de la vacuna de acuerdo con las reivindicaciones 9 a 14.

~~8/~~
131 125